{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T12:44:09Z","timestamp":1655297049091},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00120-022-01848-x","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T08:24:56Z","timestamp":1654849496000},"page":"667-680","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylaxe von \u00dcbelkeit und Erbrechen nach medikament\u00f6ser Tumortherapie"],"prefix":"10.1007","volume":"61","author":[{"given":"Hartmut","family":"Link","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"14","key":"1848_CR1","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari\u00a0RM, Aapro\u00a0M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N\u00a0Engl J Med 374(14):1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"issue":"24","key":"1848_CR2","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh\u00a0PJ, Kris\u00a0MG, Basch\u00a0E, Bohlke\u00a0K, Barbour\u00a0SY, Clark-Snow\u00a0RA et al (2020) Antiemetics: ASCO guideline update. J\u00a0Clin Oncol 38(24):2782\u20132797. https:\/\/doi.org\/10.1200\/jco.20.01296","journal-title":"J Clin Oncol"},{"key":"1848_CR3","unstructured":"Jordan K, Jahn F, Feyer P, Karthaus M, Leithold C, Oechsle K et\u00a0al (2021) Onkopedia \u2013 Antiemese bei medikament\u00f6ser Tumortherapie. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/antiemese-bei-medikamentoeser-tumortherapie\/@@guideline\/html\/index.html#litID0EE4DI. Zugegriffen: 20. Apr. 2022"},{"issue":"2","key":"1848_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito\u00a0M, Aogi\u00a0K, Sekine\u00a0I, Yoshizawa\u00a0H, Yanagita\u00a0Y, Sakai\u00a0H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a\u00a0double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115\u2013124","journal-title":"Lancet Oncol"},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"CMT.S10240","DOI":"10.4137\/cmt.S10240","volume":"8","author":"H Kitayama","year":"2016","unstructured":"Kitayama\u00a0H (2016) Granisetron transdermal system in the management of chemotherapy-induced nausea and vomiting. Clin Med Insights Ther 8:CMT.S10240. https:\/\/doi.org\/10.4137\/cmt.S10240","journal-title":"Clin Med Insights Ther"},{"issue":"2","key":"1848_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00520-015-2865-8","volume":"24","author":"YM Seol","year":"2016","unstructured":"Seol\u00a0YM, Kim\u00a0HJ, Choi\u00a0YJ, Lee\u00a0EM, Kim\u00a0YS, Oh\u00a0SY et al (2016) Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a\u00a0multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer 24(2):945\u2013952. https:\/\/doi.org\/10.1007\/s00520-015-2865-8","journal-title":"Support Care Cancer"},{"key":"1848_CR7","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1038\/srep04813","volume":"4","author":"X-F Wang","year":"2014","unstructured":"Wang\u00a0X\u2011F, Feng\u00a0Y, Chen\u00a0Y, Gao\u00a0BL, Han\u00a0B\u2011H (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep 4:4813. https:\/\/doi.org\/10.1038\/srep04813","journal-title":"Sci Rep"},{"issue":"2","key":"1848_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto\u00a0H, Abe\u00a0M, Tokuyama\u00a0O, Mizutani\u00a0H, Uchitomi\u00a0Y, Yamaguchi\u00a0T et al (2020) Olanzapine 5\u202fmg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a\u00a0multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"issue":"2","key":"1848_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari\u00a0RM, Qin\u00a0R, Ruddy\u00a0KJ, Liu\u00a0H, Powell\u00a0SF, Bajaj\u00a0M et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N\u00a0Engl J Med 375(2):134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"1848_CR10","unstructured":"Ettinger DS (2022) NCCN clinical practice guidelines in oncology\u2014antiemesis. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1415. Zugegriffen: 20. Apr. 2022"},{"issue":"7","key":"1848_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy\u00a0J, Chiew\u00a0KS, Galica\u00a0J, Pond\u00a0GR, Tannock\u00a0IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"issue":"1","key":"1848_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila\u00a0F, Warr\u00a0D, Hesketh\u00a0PJ, Gralla\u00a0R, Herrstedt\u00a0J, Jordan\u00a0K et\u00a0al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer 25(1):289\u2013294. https:\/\/doi.org\/10.1007\/s00520-016-3365-1","journal-title":"Support Care Cancer"},{"issue":"1","key":"1848_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn\u00a0LH, Rapoport\u00a0B, Navari\u00a0RM, Herrstedt\u00a0J, Brames\u00a0MJ (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25(1):303\u2013308. https:\/\/doi.org\/10.1007\/s00520-016-3449-y","journal-title":"Support Care Cancer"},{"issue":"6","key":"1848_CR14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","volume":"21","author":"IN Olver","year":"2013","unstructured":"Olver\u00a0IN, Grimison\u00a0P, Chatfield\u00a0M, Stockler\u00a0MR, Toner\u00a0GC, Gebski\u00a0V et al (2013) Results of a\u00a07-day aprepitant schedule for the prevention of nausea and vomiting in 5\u2011day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21(6):1561\u20131568. https:\/\/doi.org\/10.1007\/s00520-012-1696-0","journal-title":"Support Care Cancer"},{"issue":"7","key":"1848_CR15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ejca.2008.11.046","volume":"45","author":"K Jordan","year":"2009","unstructured":"Jordan\u00a0K, Kinitz\u00a0I, Voigt\u00a0W, Behlendorf\u00a0T, Wolf\u00a0HH, Schmoll\u00a0HJ (2009) Safety and efficacy of a\u00a0triple antiemetic combination with the NK\u20111 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45(7):1184\u20131187. https:\/\/doi.org\/10.1016\/j.ejca.2008.11.046","journal-title":"Eur J Cancer"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-022-01848-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T12:05:09Z","timestamp":1655294709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-022-01848-x"}},"subtitle":["Leitlinien zur Supportivtherapie\u00a0\u2013 Teil\u00a0II"],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1007\/s00120-022-01848-x","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>H. Link:<\/b> A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Studienleitung MMF GmbH Dortmund\/M\u00fcnster. \u2013\u00a0Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Astellas, Amgen, Chugai Pharma Marketing Ltd., Hogg Robinson Germany GmbH & Co. KG, Mundipharma, SAP, Takeda\/Shire, Teva, Viatris.\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Berater\u2011\/Gutachtert\u00e4tigkeit, wissenschaftliches Advisory Board, Fortbildungsprojekte, Gutachter | ACCORD HEALTCARE LIMITED, Apogepha, Europharma, G1\u00a0Therapeutics, Hexal, Accord Deutschland, Johnson & Johnson, Lindis Blood Care, Mundipharma, onkowissen.de, Pharmacosmos, Servier Deutschland GmbH, Shire Deutschland GmbH, Takeda Group, SIGAL SMS. \u2013\u00a0Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Onkopti, Therapieprotokolldatenbank, Onkodin GmbH.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ehem. Chefarzt Westpfalz-Klinikum, H\u00e4matologie, Internistische Onkologie, Stammzelltransplantation, Akademisches Lehrkrankenhaus der Universit\u00e4ten Mainz und Heidelberg, Sprechstunde f\u00fcr H\u00e4matologie und internistische Onkologie Kaiserslautern, Ethikkommission Landes\u00e4rztekammer Rheinland-Pfalz, Deutsche Krebsgesellschaft (DKG), Arbeitsgemeinschaft Internistische Onkologie (AIO), Leitung der AG Supportivtherapie | Leitung der AG Digitalisierung, Arbeitsgemeinschaft Supportive Ma\u00dfnahmen in der Onkologie (AGSMO), Mitglied des Leitungsgremiums, Sekret\u00e4r des Onkologischen Zentrums Westpfalz (OZW), Vorsitzender des F\u00f6rdervereins Mama-Papa-hat-Krebs Kaiserslautern.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}